
Preparing for an upcoming appointment
Attending a medical appointment can be daunting for some people. It is [...]
READ MOREMarch 2023 – Results from a phase I study presented at the American Society for Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium showed promising clinical activity with long-lasting responses for a novel combination immunotherapy regimen among heavily pretreated patients with microsatellite stable metastatic colorectal cancer (mCRC). The combination therapy consisted of two immunotherapies – botensilimab (Agenus) and balstilimab (Agenus).
What is microsatellite stable metastatic colorectal cancer?
When a colorectal tumour undergoes biomarker testing or molecular profiling, microsatellite status will be assessed. Molecular profiling examines a tumour for the presence of specific biomarkers that can help guide a patient’s treatment. A colorectal tumour will either be microsatellite instability high (MSI-H)/mismatch repair deficient (dMMR) or microsatellite stable (MSS) / mismatch repair proficient (pMMR). Microsatellite instability is found most often in colorectal cancer, gastric cancer, and endometrial cancer, but it may also be found in many other types of cancer. Knowing whether cancer is microsatellite instability-high may help plan the best treatment.
Mismatch repair refers to the repair pathway that exists in our cells to repair mistakes that have occurred when our DNA (genetic material) is replicated (copied), or during normal DNA repair that occurs when our DNA gets damaged. MSS/pMMR represents the normal state of the cell with a properly functioning (“proficient”) mismatch repair pathway. The majority of colorectal cancer patients have MSS tumours – about 85% of all-stage CRC and about 96% of stage IV mCRC are MSS.
MSS tumours have been referred to as “cold” tumours because they generally do not respond to treatment with immunotherapy. MSI-H or deficient mismatch repair (dMMR) is the mutated state where the mismatch repair pathway is not functioning normally. Colorectal tumours that are positive for the MSI-H/dMMR biomarker – about 15% of all CRC and 4% of stage IV mCRC – are more likely to experience benefit from treatment with immunotherapy.
The study
In this study, the researchers treated a small group (70) of heavily pretreated (patients who had received several previous therapies) MSS mCRC patients with the combination of botensilimab and balstilimab. Typically, immunotherapies (also referred to as checkpoint inhibitors) do not work in MSS colorectal cancer tumours. The combination treatment, however, showed impressive efficacy, with over 70% disease control rate, which indicates the percentage of patients that achieved stable disease that does not shrink or grow significantly over a certain period of time. Over 20% of patients had objective response rates, some of which were near complete responses (the disappearance of all signs of cancer in the body) and many of which were long-lasting effects. The 12-month overall survival rate was 63%. It is important to note that the patients who experienced the greatest benefit from the combination were those that did not have any active metastasis in their liver. The combination treatment was also well tolerated by patients in terms of toxicities.
Interpretation of study results
These results are meaningful because they show very promising activity in heavily pretreated patients with MSS mCRC that otherwise would have few treatment options available to them. After not responding to multiple lines of previous treatment, these patients would only be candidates for weakly effective treatments like trifluridine/tipiracil (Lonsurf) or regorafenib (Stivarga).
Phase 2 of this study has already been launched with various trial sites opening. The second phase of the study is a randomized trial (patients will be randomly assigned to receive the various treatment arms under investigation) that will examine two different doses of the combination treatment and compare them to the standard of care, which consists of either regorafenib or Lonsurf. “It’s a very effective combination, a very safe combination when management of toxicity is done carefully, and it really is so much better – in a non-comparative sense- than Lonsurf or regorafenib. We will see in the randomized phase 2 if that will come to fruition, but as someone who has given a lot of Lonsurf, a lot of regorafenib and a lot of this drug – it’s just in a different league”, says lead study author Benjamin L. Schlecter, MD, of the Dana-Farber Cancer Institute.
Attending a medical appointment can be daunting for some people. It is [...]
READ MOREApril 2023 A recent study published in JAMA Oncology found that amo [...]
READ MOREApril 2023 A recent study published in JAMA Network Open showed tha [...]
READ MOREMarch 2023 -A German study published in BMC Cancer explored the emotio [...]
READ MOREJanuary 2023 There is increasing evidence to support the use of cir [...]
READ MOREJanuary 2023 Findings from the phase III SUNLIGHT trial were presente [...]
READ MORELocations: BC, AB, ON, QC Status: currently recruiting Trial descr [...]
READ MORENovember 2022 A new study involving patients with different cancer [...]
READ MORENovember 2022 To better understand the role of the gut microbiome i [...]
READ MOREOctober 2022 A recent study published in the Journal of the Nationa [...]
READ MOREEarlier this month, controversial news headlines emerged: “Colonoscopi [...]
READ MORELocation: Canada-wide Status: Currently recruiting Trial Descrip [...]
READ MOREFindings from the global FRESCO-2 trial showed that a drug called fruq [...]
READ MOREFindings from a study published in the Journal of Clinical Oncology de [...]
READ MOREUlcerative colitis is a chronic inflammatory bowel disease that affect [...]
READ MORECrohn’s disease is a chronic (long-term) inflammatory disease that can [...]
READ MOREIn this Q&A, Dr. Brandon Sheffield, Pathologist with the William O [...]
READ MOREIn this Q&A, Suzanne Zwicker, Clinical Pharmacist on the National [...]
READ MOREJuly 2022 The annual ESMO World Congress on Gastrointestinal (GI) C [...]
READ MOREJuly 2022 Patients who have colorectal cancer that has spread to th [...]
READ MOREJune 2022 Minimal residual disease (MRD) is a term that refers to cance [...]
READ MOREMay 2022. Image source: https://www.whathealth.com/breastcancer/her2rec [...]
READ MOREMay 2022 The KEYNOTE-177 trial is a landmark study in colorectal ca [...]
READ MOREApril 2022. A new study from Australia found that heavy drinking in [...]
READ MOREApril 2022. A study published in JAMA Network Open investigated whe [...]
READ MOREMarch 2022. While obesity is a known risk factor for colorectal can [...]
READ MOREhttps://youtu.be/-Oi2jBJDUNc February 2022. Join Patient Support Spe [...]
READ MOREJanuary 2022 Total neoadjuvant therapy (TNT) is a standard approach [...]
READ MOREJanuary 2022 Oxaliplatin is an important intravenous chemotherapy d [...]
READ MOREJanuary 2022. Laura Ferguson, a current ileostomy patient, and Karen Br [...]
READ MOREJoin Chana, our Patient Support Specialist, as she sits down to a cand [...]
READ MOREJoin Dr. Scott Berry, Professor & Department Head, Department of O [...]
READ MORELeft: Laura A. Dawson, MD, FRCPC, Princess Margaret Cancer Centre/Univ [...]
READ MOREThis month, the Food and Drug Administration (FDA) cleared an investig [...]
READ MOREIn 2016, the United States Preventive Services Task Force (U [...]
READ MOREIn 2020, Jason was diagnosed with stage 3b colorectal cancer at age 36. In [...]
READ MOREDr. Megan Bernard, naturopathic doctor, discusses a variety of tips and su [...]
READ MORENutritionist Jill Haverstock discusses a variety of tips and suggestions t [...]
READ MOREDr. Mel Borins is a family practitioner based in Toronto, Ontario. He crea [...]
READ MOREJason Abramovitch is an early age onset stage 3b colon cancer survivor who [...]
READ MOREOn December 3rd 2021, Physiotherapist Thi Tran gave a compelling session o [...]
READ MORENovember 2021 Findings from a recent study published in JAMA Networ [...]
READ MORENovember 2021 Findings from phase II of the CheckMate-142 trial sho [...]
READ MOREThe EPOCH trial is the first phase III international study evaluating the [...]
READ MOREImmunotherapy has revolutionized the way cancer is treated by boosting [...]
READ MOREColorectal (CRC) cancer screening and diagnosis during the COVID-19 pa [...]
READ MOREA Swedish population study published this month in the Journal of the [...]
READ MOREAdjuvant (post-surgical) chemotherapy is useful in reducing the risk o [...]
READ MOREThe fecal immunochemical test (FIT) is a widely used colorectal cancer [...]
READ MORENew findings from a study presented at the European Society for Medica [...]
READ MOREWhile many different risk factors for colorectal cancer (CRC) have bee [...]
READ MOREFindings from a recent study show that multigene panel testing of patients [...]
READ MOREThe final recommendation from the United States Preventive Services Ta [...]
READ MOREPeriodontal disease (PD) is a set of inflammatory conditions that affect t [...]
READ MOREThe US Food and Drug Administration (FDA) recently approved the market [...]
READ MOREWe've posted some new recipe videos on our sister site, Foods that Fight C [...]
READ MOREThe Ontario Cancer Research Institute (OICR) held a conference on Tran [...]
READ MOREApril is Diversity Month dedicated to celebrating and honouring all in [...]
READ MOREResults from a systematic review published in JAMA Oncology found that [...]
READ MOREA study published in the Journal of Clinical Oncology Precision Oncology s [...]
READ MOREMolecular profiling in gastrointestinal (GI) cancer has been named by [...]
READ MOREYour physical, emotional and mental well-being are vital to your ability t [...]
READ MORENew findings from the University of Alberta published in the Journal of th [...]
READ MOREFindings from a recent study presented at the 2021 Gastrointestinal Ca [...]
READ MOREColorectal cancer is the second most diagnosed cancer in Canada. Twent [...]
READ MORE10 December 2020Findings from a recent study showed that people who regula [...]
READ MORE22 December 2020 Hepatic Artery Infusion (HAI) chemotherapy is sometime [...]
READ MORENovember 2020 Findings from a recent study conducted by the Mayo Clinic [...]
READ MOREThe non-surgical management or “watch-and-wait” approach for rectal c [...]
READ MOREThe incidence of colorectal cancer (CRC) is rising among young adults, who [...]
READ MOREOpportunity to Investigate the Microbiome’s Impact on Science and Treatmen [...]
READ MORENew findings from a study conducted at the University of Sheffield in [...]
READ MORESexuality and relationships during and after cancer is extremely impor [...]
READ MOREChadwick Boseman’s death from colorectal cancer (CRC) at age 43 was a shoc [...]
READ MOREToday, Wednesday September 30th, is World Metastatic Colorectal Cancer Day [...]
READ MOREDr. Heinz-Josef Lenz, MD, discusses optimal sequencing strategies for [...]
READ MOREThe European Society for Medical Oncology ESMO Virtual Congress 2020 t [...]
READ MOREJesse Fishman is a 17-year-old hockey player, currently playing for the Ki [...]
READ MORE12 August 2020 Recent findings from a Swedish cohort study found that p [...]
READ MOREIt was the day of the lockdown. My family doctor called. “The colorectal c [...]
READ MOREFill out the survey! The world was shocked late last week as we learned a [...]
READ MOREPrevious data have shown that certain species of intestinal bacteria not o [...]
READ MOREAs we transition into autumn, take a moment to appreciate the seasonal pro [...]
READ MOREThe COVID-19 pandemic has presented countless new challenges in cancer car [...]
READ MOREThe COVID-19 pandemic situation is constantly evolving. Canada is slowly r [...]
READ MOREResults of several new studies provide important perspectives on the use o [...]
READ MOREIn the past two years, findings from important clinical trials are shaping [...]
READ MOREHold the Date! On behalf of Colorectal Cancer Canada (CCC), you are cordi [...]
READ MOREWhat is Lynch Syndrome? Lynch syndrome is a genetically inherited conditi [...]
READ MORECoronavirus has taken the world by storm since the beginning of 2020, and [...]
READ MORETo ensure the health and safety of our participants, volunteers, staff and [...]
READ MOREThe American Society of Clinical Oncology (ASCO) held its annual meeting a [...]
READ MOREIn just a few months, coronavirus (COVID-19) has transformed our lives. De [...]
READ MOREIt has been known for millennia that what we eat can be powerful medicine [...]
READ MOREThe last few decades have seen important advances in colorectal cancer tre [...]
READ MORECo-leads of Push For Your Tush Ottawa share their connection to the cause [...]
READ MOREThe Centre de recherche of the Centre hospitalier universitaire de Sherbro [...]
READ MOREOn June 24, 2019, colorectal cancer screening in Ontario is changing to th [...]
READ MOREToday we remember Dr. Henry Lynch, esteemed researcher and father of hered [...]
READ MOREOn Tuesday, July 16, Colorectal Cancer Canada (CCC) held our third annual [...]
READ MOREResearchers with the World Health Organization confirm increased rates of [...]
READ MORELast Thursday and Friday, Morgan Kennedy, CCC’s Never Too Young Program Ma [...]
READ MOREColorectal Cancer Canada (CCC) is proud to announce the publication of the [...]
READ MOREToday, the Giant Colon Tour stopped at the University of Montreal Hospital [...]
READ MOREMost people do not know that cancer is the number one cause of death among [...]
READ MOREMarch is Colorectal Cancer Awareness Month! Colorectal cancer may touch yo [...]
READ MORE